CYPHERPUNK TECHNOLOGIES INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 0.00 shares.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 6.67K shares, a 36.85% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 6.67K shares, a 80.79% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 34.70K shares.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 2.29K shares, a 93.01% decline from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 32.78K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 6.67K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 30.81K shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 30.81K shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2025-03-31 | 6.67K shares 10-Q · filed 2025-05-13 | 30.81K shares derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | 24.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 34.70K shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 10.56K shares 10-Q · filed 2024-05-13 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 2.29K shares 10-K · filed 2023-03-24 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | 32.78K shares 10-K · filed 2022-03-11 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2020-06-30 | 25.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | |
| 2020-03-31 | 7.78K shares 10-Q · filed 2020-05-14 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 2.48K shares 10-K · filed 2020-03-16 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | 3.51K shares 10-K · filed 2019-04-01 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |